{"id":1863,"date":"2016-08-05T13:03:07","date_gmt":"2016-08-05T10:03:07","guid":{"rendered":"https:\/\/www.aenorasis.com\/en\/products\/medical-devices-diagnostics\/laboratory-sector\/clart-cma\/"},"modified":"2016-10-07T10:46:11","modified_gmt":"2016-10-07T07:46:11","slug":"clart-cma","status":"publish","type":"page","link":"https:\/\/www.aenorasis.com\/en\/products\/medical-devices-diagnostics\/laboratory-sector\/clart-cma\/","title":{"rendered":"CLART CMA"},"content":{"rendered":"<p><strong>CLART CMA is a method of molecular biology. The kit includes the reagents for amplification and detection\/ identification of the most frequent mutations of oncogenes in the signaling pathway of EGFR.<\/strong><\/p>\n<p>The mutations that the kit detects\/identifies are the following: <\/p>\n<p><strong>\u2014 KRAS:G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H, Q61L<\/strong><br \/>\n <strong>\u2014 BRAF: V600E, V600K <\/strong><br \/>\n <strong>\u2014 PI3K: E542K, E545D, E545K, H1047R<\/strong><\/p>\n<p>The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform:  CLART (Clinical Array Technology). The platform is based on low density micro-arrays placed at the bottom of the micro vial tube. <\/p>\n<p>The kit detects 9 mutations of the Kras gene in codons 12,13 and 61, 2 mutations of the Bras gene in codon 600 and 4 mutations of the PI3K gene in codons 9 and 20 in paraffin embedded samples (FFPE, formalin fixed paraffin embedded). All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample.<\/p>\n<hr \/>\n<h1><strong>CLART iKras \u2013 Nras <\/strong><\/h1>\n<p>CLART CMA is a method of molecular biology. The kit includes the reagents for amplification and detection\/ identification of the most frequent mutations of oncogene Nras in the signaling pathway of EGFR.<\/p>\n<p>The mutations that the kit detects\/identifies are the following:<\/p>\n<p><strong>\u2014\u00a0Nras: G12D,\u00a0Q61H (183 A&gt;T),\u00a0Q61R,\u00a0Q61K,Q61L,\u00a0K117N (351 G&lt;C),\u00a0A146T<br \/>\n \u2014\u00a0Kras (infrequent): Q61H (183 A&gt;C),\u00a0K117N (351 A&gt;C),\u00a0K117N (351 A&gt;T),\u00a0A146V,\u00a0A146T<\/strong><\/p>\n<p>Sample: colorectal biopsies<\/p>\n<p>The kit detects 10 mutations associated to the answer on the treatment of patients with metastatic colorectal cancer.<\/p>\n<p>The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform:  CLART (Clinical Array Technology). The platform is based on low density microarrays placed at the bottom of the micro vial tube.<\/p>\n<p>All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample. <\/p>\n<hr \/>\n<h1><strong>CLART<\/strong> <strong>Kras<\/strong><strong> \u2013 <\/strong><strong>Braf<\/strong><strong> \u2013 <\/strong><strong>PI<\/strong><strong>3<\/strong><strong>K<\/strong><\/h1>\n<p>CLART Kras \u2013 Braf \u2013 PI3K<sup>1<\/sup> is a method of molecular biology. The kit includes the reagents for amplification and detection\/ identification of the most frequent mutations of oncogenes in the signaling pathway of EGFR. <\/p>\n<p>The mutations that the kit detects\/identifies are the following: <\/p>\n<p><strong>\u2014\u00a0KRAS: G12A, G12C, G12D, G12R, G12S, G12V,G13D, Q61H, Q61L<\/strong><br \/>\n <strong>\u2014\u00a0BRAF: V600E,\u00a0V600K<\/strong><br \/>\n <strong>\u2014\u00a0PI3K:\u00a0 E542K,\u00a0E545D,\u00a0E545K,\u00a0H1047R<\/strong><\/p>\n<p>The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform:  CLART (Clinical Array Technology). The platform is based on low density micro-arrays placed at the bottom of the micro vial tube.<\/p>\n<p>The kit detects 9 mutations of the Kras gene in codons 12,13 and 61, 2 mutations of the Bras gene in codon 600 and 4 mutations of the PI3K gene in codons 9 and 20 in paraffin embedded samples (FFPE, formalin fixed paraffin embedded). All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample. <\/p>\n<blockquote><p>References:<br \/>\n1. CLART\u00ae CMA KRAS\u00b7BRAF\u00b7PI3K, DETECTION AND GENETIC IDENTIFICATION OF POINT MUTATIONS IN 3 OF THE GENES BELONGING TO THE EGFR PATHWAY ASSOCIATED TO COLORECTAL CANCER -KRAS, BRAF AND PI3K FOR IN VITRO DIAGNOSIS<\/p><\/blockquote>\n<hr \/>\n<h1>CLART EGFR<\/h1>\n<p>CLART CMA is a method of molecular biology. The kit includes the reagent for the amplification and the detection\/ identification of 40 point mutations associated to the response to treatment of patients with non small-cell lung cancer.<\/p>\n<p>The mutations that the kit detects\/identifies are the following:  <\/p>\n<p><strong>\u2014 Exon18: G719A,\u00a0G719C,\u00a0G719s<\/strong><br \/>\n <strong>\u2014 Exon19:\u00a0Complex Deletions and Mutations *<\/strong><br \/>\n <strong>\u2014 Exon20: \u00a0S768T, T790M, 2319_2320insCAC, D770_N771insG, V769_D770insASV, V770_N771insSVD<br \/>\n \u2014 Exon21: \u00a0L858R, L861Q<br \/>\n <\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-1200\" src=\"https:\/\/www.aenorasis.com\/wp-content\/uploads\/2016\/08\/fet9.jpg\" alt=\"fet9\" width=\"1050\" height=\"51\" srcset=\"https:\/\/www.aenorasis.com\/wp-content\/uploads\/2016\/08\/fet9.jpg 1050w, https:\/\/www.aenorasis.com\/wp-content\/uploads\/2016\/08\/fet9-300x15.jpg 300w, https:\/\/www.aenorasis.com\/wp-content\/uploads\/2016\/08\/fet9-1024x50.jpg 1024w, https:\/\/www.aenorasis.com\/wp-content\/uploads\/2016\/08\/fet9-768x37.jpg 768w\" sizes=\"auto, (max-width: 1050px) 100vw, 1050px\" \/><\/p>\n<p>The amplification product, which is the result of the polymerase chain reaction technique (PCR), is detected with the use of a new technological platform:  CLART (Clinical Array Technology). The platform is based on low density micro-arrays placed at the bottom of the micro vial tube.<\/p>\n<p>All amplification tubes include internal control of DNA extraction and confirmation of DNA extraction, as well as internal control to confirm DNA amplification of the sample. <\/p>\n<blockquote><p>References:<br \/>\n1. CLART\u00ae CMA EGFR, DETECTION AND GENETIC IDENTIFICATION OF POINT MUTATIONS, INSERTIONS AND DELETIONS IN THE GENE EGFR PATHWAY ASSOCIATED TO NON SMALL CELL LUNG CANCER FOR IN VITRO DIAGNOSIS<\/p><\/blockquote>\n<hr \/>\n<p><strong>Colorectal cancer<\/strong><\/p>\n<p>Colorectal cancer constitutes a major public health issue and it is one of the main causes of fatality by malignancies in the western world. It is the second most frequent tumor in the developed countries. It is known that Kras oncogene mutations are a negative predictive factor for response to anti-EGFR treatment on metastatic colorectal cancer.  Braf detection is also important for the same reason.<\/p>\n<p>CLART CMA test detects and, at the same time, identifies the mutations of Kras, Braf and PI3K oncogenes.<br \/>\nThis test offers the necessary knowledge for the correct identification of patients with metastatic colorectal cancer that respond to anti-EGFR monoclone antibodies treatment.<br \/>\nIt also helps to chose an individual focused treatment.\n<\/p>\n<blockquote><p>References<br \/>\n1.\u0395\u03b8\u03bd\u03b9\u03ba\u03cc \u03a3\u03c7\u03ad\u03b4\u03b9\u03bf \u0394\u03c1\u03ac\u03c3\u03b7\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03bf\u03bd \u039a\u03b1\u03c1\u03ba\u03af\u03bd\u03bf 2011-2015, \u03a5\u03c0\u03bf\u03c5\u03c1\u03b3\u03b5\u03af\u03bf \u03a5\u03b3\u03b5\u03af\u03b1\u03c2 http:\/\/www.anticancer.gov.gr\/pages\/5 <\/p>\n<p>2.National Institute for Health and Care Excellence Diagnostics consultation document KRAS mutation testing of tumours in adults with metastatic colorectal cancer, https:\/\/www.nice.org.uk\/guidance\/gid-dt14\/documents\/kras-mutation-testing-of-tumours-in-adults-with-metastatic-colorectal-cancer-diagnostics-consultation-document-pdf2<\/p><\/blockquote>\n<hr \/>\n<p><strong>The information referred to for general information and informing the public and in any case can not replace a doctor or other suitably qualified health professional. The responsibility of the media carries by ENORASIS SA<\/strong><\/p>\n<hr \/>\n","protected":false},"excerpt":{"rendered":"<p>CLART CMA is a method of molecular biology. The kit includes the reagents for amplification and detection\/ identification of the most frequent mutations of oncogenes in the signaling pathway of EGFR. The mutations that the kit detects\/identifies are the following: \u2014 KRAS:G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61H, Q61L&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":1855,"menu_order":33,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_seopress_titles_title":"CLART CMA, method of molecular biology - Aenorasis","_seopress_titles_desc":"CLART CMA is a method of molecular biology. Includes the reagents for amplification of the most frequent mutations of oncogenes in the pathway of EGFR.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"CLART CMA","footnotes":""},"class_list":["post-1863","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/pages\/1863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/comments?post=1863"}],"version-history":[{"count":0,"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/pages\/1863\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/pages\/1855"}],"wp:attachment":[{"href":"https:\/\/www.aenorasis.com\/en\/wp-json\/wp\/v2\/media?parent=1863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}